News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antibe Therapeutics Inc. Announces Discontinuation Of Latin American Letter Of Intent


4/1/2014 1:56:30 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces that discussions with the potential Latin American partner with which it executed an LOI in 2012 have been discontinued due to a recent change in the potential partner’s management and corporate strategy. Antibe’s CEO Dan Legault stated, “Although we were looking forward to working with this partner, we are gratified that our work on ATB-346 was validated by their due diligence studies. We are moving quickly into our next phase of development while continuing discussions with our other potential partners”. With the completion of its planned pre-clinical program, Antibe is on schedule to initiate its first-in-human trials in June, pending regulatory approval, and is continuing its regional partnering strategy including ongoing discussions with potential clinical partners.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES